期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 22, 期 11, 页码 1966-1983出版社
WILEY
DOI: 10.1002/ejhf.2017
关键词
Biomarkers; Cardio-oncology; Cardiotoxicity; Heart failure; Myocarditis; Cardiac troponin; B-type natriuretic peptides; Anthracyclines; HER2-targeted therapies; Vascular endothelial growth factor inhibitors; Proteasome inhibitors; Immune checkpoint inhibitors; Radiotherapy
资金
- Fondation Leducq Network of Excellence in Cardio-Oncology
- grant 'Ricerca di Ateneo Federico II 2017'
- NIH [R56 HL141466, R01 HL141466]
- European Research Council [ERC CoG 818715]
- Netherlands Heart Foundation [2014-40, 2017-21, 2017-11, 2018-30]
- Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI) [917.13.350]
- project INOMED - European Union [CZ.02.1.01/0.0/0.0/18_069/0010046]
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据